Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Future Market Size Estimation For The Dry Age Related Macular Degeneration (AMD) Market Covering 2025–2034?
The dry age related macular degeneration (amd) market has seen significant expansion in recent years. It is projected to increase from $4.49 billion in 2024 to $4.89 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.8%. This historical development can be ascribed to an expanding elderly demographic, a greater occurrence of chronic conditions, heightened consciousness regarding eye health, an increasing volume of clinical investigations centered on dry AMD, and a rising preference for less intrusive treatment approaches.
The dry age related macular degeneration (amd) market size is projected to experience robust expansion in the coming years. It is expected to reach $6.8 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.6%. This anticipated growth throughout the forecast period can be attributed to the emergence of novel therapies, increasing healthcare expenditure, the rising utilization of laser photocoagulation therapy, advancements in genetic research, and an escalating focus on personalized medicine. Furthermore, significant trends for the forecast period include progress in diagnostic technologies, a rising adoption of teleophthalmology, technologically advanced treatments, various product approvals, and the launch of new products.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21176&type=smp
Which Factors And Drivers Are Influencing The Dry Age Related Macular Degeneration (AMD) Market In 2025?
The increasing elderly demographic is anticipated to stimulate the expansion of the dry age related macular degeneration (AMD) market moving forward. The term “geriatric population” refers to older individuals, typically defined as those aged 65 years and older. The rise in the geriatric population is attributed to several factors, including advancements in medical technology, more effective management of chronic illnesses, longer life expectancy, and enhanced geriatric care. Dry age-related macular degeneration (AMD) benefits the older adult population by offering specific treatments and management approaches aimed at slowing the disease’s progression, maintaining vision, and enhancing the quality of life for seniors affected by this condition. For example, reports published in June 2024 by the National Council on Aging, a US-based organization, indicated that in 2022, approximately 57.8 million adults were aged 65 and above, making up 17.3% of the total U.S. population. This represented an increase from 16.9% in 2021. Consequently, the expanding geriatric population will propel the growth of the dry age-related macular degeneration (AMD) market.
What Are The Major Segments Identified In The Dry Age Related Macular Degeneration (AMD) Market?
The dry age related macular degeneration (amd)market covered in this report is segmented –
1) By Stages: Early Age-Related Macular Degeneration; Intermediate Age-Related Macular Degeneration; Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years; Above 60 Years; Above 40 Years
3) By Route Of Administration: Oral; Injectables
4) By End Users: Hospitals And Clinics; Diagnostic Centers; Academic And Research Institutes
Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation; Retinal Pigment Epithelium Changes
2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits; Increased Pigmentary Abnormalities
3) By Late Age-Related Macular Degeneration: Geographic Atrophy; Central Vision Loss
Which Competitive Trends Are Defining The Dry Age Related Macular Degeneration (AMD) Market Structure?
Companies operating in the dry age-related macular degeneration (AMD) market are intensely focused on developing new advanced technologies and treatments, such as light delivery systems, aimed at targeting and activating retinal cells to potentially slow the disease’s progression. Light delivery systems refer to technologies specifically designed to transmit light for various therapeutic applications, particularly within medical treatments. For instance, in January 2024, LumiThera Inc., a US-based medical device company, launched photobiomodulation (PBM) for dry age-related macular degeneration (AMD) with its Valeda Light Delivery System. This is notable as it represents the first FDA-authorized therapy developed to address vision loss in patients suffering from dry AMD, a condition for which treatment options are currently limited. LumiThera subsequently initiated the EUROLIGHT registry study to gather comprehensive long-term data on the outcomes of patients treated with the Valeda system. The Valeda system itself utilizes a multi-wavelength light delivery method, employing three specific wavelengths (590 nm, 660 nm, and 850 nm). This non-invasive treatment can be administered through either an open or closed eyelid and typically involves nine sessions over a period of three to four weeks.
Which Major Firms Are Strengthening Their Position In The Dry Age Related Macular Degeneration (AMD) Industry?
Major companies operating in the dry age related macular degeneration (AMD) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Alimera Sciences Inc., Apellis Pharmaceuticals Inc., Belite Bio Inc., Axol Bioscience Ltd., Alkeus Pharmaceuticals Inc., Kubota Holdings Co., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc.
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Dry Age Related Macular Degeneration (AMD) Industry?
North America was the largest region in the dry age-related macular degeneration (AMD) market in 2024. The regions covered in the dry age related macular degeneration (AMD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Dry Age Related Macular Degeneration (AMD) Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21176&type=smp
Browse Through More Reports Similar to the Global Dry Age Related Macular Degeneration (AMD) Market 2025, By The Business Research Company
Macular Degeneration Treatment Global Market Report 2025
Age Related Macular Degeneration Global Market Report 2025
Cartilage Degeneration Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cartilage-degeneration-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model